Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (alliance) Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Paclitaxel

abstract

  • This trial did not show noninferiority of T to AC, a conclusion that is unlikely to change with additional events and follow-up. T was less toxic than AC.

publication date

  • August 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4105484

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.53.7142

PubMed ID

  • 24934787

Additional Document Info

start page

  • 2311

end page

  • 7

volume

  • 32

number

  • 22